Effectiveness of pentavalent and monovalent rotavirus vaccines in concurrent use among US children <5 years of age, 2009-2011

Clinical Infectious Diseases

Volumn 57, Issue 1, 2013, Pages 13-20

  Payne, Daniel C ^a   Boom, Julie A ^b,c   Staat, Mary Allen ^d   Edwards, Kathryn M ^e   Szilagyi, Peter G ^f   Klein, Eileen J ^g   Selvarangan, Rangaraj ^h   Azimi, Parvin H ⁱ   Harrison, Christopher ^h   Moffatt, Mary ^h   Johnston, Samantha H ⁱ   Sahni, Leila C ^b   Baker, Carol J ^b,c   Rench, Marcia A ^b,c   Donauer, Stephanie ^d   McNeal, Monica ^d   Chappell, James ^e   Weinberg, Geoffrey A ^f   Tasslimi, Azadeh ^j   Tate, Jacqueline E ^a   Wikswo, Mary ^a   Curns, Aaron T ^a   Sulemana, Iddrisu ^a   Mijatovic Rustempasic, Slavica ^a   Esona, Mathew D ^a   Bowen, Michael D ^a   Gentsch, Jon R ^a   Parashar, Umesh D ^a   more..

^a NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

^b TEXAS CHILDREN S HOSPITAL   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^e VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^f UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^g SEATTLE CHILDREN S HOSPITAL   (United States)

^h CHILDREN S MERCY HOSPITAL   (United States)

ⁱ CHILDREN S HOSPITAL OAKLAND   (United States)

^j WASHINGTON STATE DEPARTMENT OF HEALTH   (United States)

more..

Author keywords

New Vaccine Surveillance Network; RotaTeq; rotavirus; vaccine

Indexed keywords

ROTAVIRUS VACCINE;

ACUTE GASTROENTERITIS; ARTICLE; CHILD; CHILD HOSPITALIZATION; DRUG EFFICACY; EMERGENCY WARD; ENZYME IMMUNOASSAY; ETHNICITY; FECES ANALYSIS; FEMALE; GENOTYPE; HOSPITAL PATIENT; HUMAN; INFANT; INFECTION PREVENTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; ROTAVIRUS INFECTION; SCHOOL CHILD; UNITED STATES; VIRUS STRAIN;

NEW VACCINE SURVEILLANCE NETWORK; ROTATEQ; ROTAVIRUS; VACCINE;

AMBULATORY CARE; CHILD, PRESCHOOL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FECES; FEMALE; GASTROENTERITIS; GENOTYPE; HOSPITALIZATION; HUMANS; INFANT; MALE; ROTAVIRUS; ROTAVIRUS INFECTIONS; ROTAVIRUS VACCINES; UNITED STATES; VACCINES, ATTENUATED;

EID: 84878833984     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cit164     Document Type: Article

References (26)

1. Widdowson MA, Meltzer MI, Xang X, et al. Cost effectiveness and potential impact of rotavirus vaccination in the United States. Pediatrics 2007; 119:684-97. (Pubitemid 46556667)
2. Widdowson MA, Meltzer M. Update on cost-effectiveness of rotavirus vaccination in the United States. Atlanta, GA: Advisory Committee for Immunization Practices, 2008.
3. Centers for Disease Control and Prevention. Prevention of rotavirus gastroenteritis among infants and children: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2009; 58:1-26.
4. Tate JE, Panozzo CA, Payne DC, et al. Decline and change in seasonality of US rotavirus activity after the introduction of rotavirus vaccine. Pediatrics 2009; 124:465-71.
5. Tate JE, Mutuc JD, Panozzo CA, et al. Sustained decline in rotavirus detections in the United States following the introduction of rotavirus vaccine in 2006. Pediatr Infect Dis J 2011; 30(1 suppl):S30-4.
6. Cortese MM, Tate JE, Simonsen L, et al. Reduction in gastroenteritis in United States children and correlation with early rotavirus vaccine uptake from national medical claims databases. Pediatr Infect Dis J 2010; 29:489-94.
7. Tate JE, Cortese MM, Payne DC, et al. Uptake, impact, and effectiveness of rotavirus 21 vaccination in the United States: review of the first 3 years of postlicensure data. Pediatr Infect Dis J 2011; 30(1 suppl):S56-60.
8. Payne DC, Staat MA, Edwards KM, et al. Direct and indirect effects of rotavirus vaccination upon childhood hospitalizations in 3 US counties, 2006-2009. Clin Infect Dis 2011; 53:245-53.
9. Ruiz-Palacios GM, Pérez-Schael I, Velázquez FR, et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med 2006; 354:11-22. (Pubitemid 43048947)
10. Linhares AC, Velázquez FR, Pérez-Schael I, et al. Efficacy and safety of an oral live attenuated human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in Latin American infants: a randomised, double-blind, placebo-controlled phase III study. Lancet 2008; 371:1181-9. (Pubitemid 351458523)
11. Vesikari T, Karvonen A, Puustinen L, et al. Efficacy of RIX 4414 live attenuated human rotavirus vaccine in Finnish infants. Pediatr Infect Dis J 2004; 23:937-43. (Pubitemid 40812781)
12. Vesikari T, Karvonen A, Prymula R, et al. Efficacy of human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in European infants: randomized, double-blind controlled study. Lancet 2007; 370:1757-63. (Pubitemid 350137490)
13. Payne DC, Staat MA, Edwards KM, et al. Active, population-based surveillance for severe rotavirus gastroenteritis in children in the United States. Pediatrics 2008; 122:1235-43.
14. Payne DC, Szilagyi P, Staat MA, et al. Secular variation in US rotavirus disease rates and serotypes: implications for assessing the rotavirus vaccination program. Pediatr Infect Dis J; 2009; 28:948-53.
15. Poehling KA, Edwards KM, Weinberg GA, et al. The underrecognized burden of influenza in young children. N Engl J Med 2006; 355:31-40.
16. Das BK, Gentsch JR, Cicirello HG, et al. Characterization of rotavirus strains from newborns in New Delhi, India. J Clin Microbiol 1994; 32:1820-2. (Pubitemid 24189584)
17. Griffin DD, Nakagomi T, Hoshino Y, et al. Characterization of nontypeable rotavirus strains from the United States: identification of a new rotavirus reassortant (P2A[6], G12) and rare P3[9] strains related to bovine rotaviruses. Virology 2002; 294:256-69. (Pubitemid 34920524)
18. Gentsch JR, Glass RI,Woods P, et al. Identification of group A rotavirus gene 4 types by polymerase chain reaction. J Clin Microbiol 1992; 30:1365-73.
19. Gouvea V, Glass RI, Woods P, et al. Polymerase chain reaction amplification and typing of rotavirus nucleic acid from stool specimens. J Clin Microbiol 1990; 28:276-82. (Pubitemid 20050935)
20. Staat MA, Payne DC, Donauer S, et al. Effectiveness of pentavalent rotavirus vaccine against severe disease. Pediatrics 2011; 128: e267-75.
21. Boom JA, Tate JE, Sahni LC, et al. Effectiveness of pentavalent rotavirus vaccine in a large urban population in the United States. Pediatrics 2009; 125:e199-207.
22. Boom JA, Tate JE, Sahni LC, et al. Sustained protection from pentavalent rotavirus vaccination during the second year of life at a large, urban US pediatric hospital. Pediatr Infect Dis J 2010; 29:1-3.
23. Cortese MM, LeBlanc J, White KE, et al. Leveraging state immunization information systems to measure the effectiveness of rotavirus vaccines. Pediatrics 2011; 128:e1474-81.
24. Field EJ, Vally H, Grimwood K, et al. Pentavalent rotavirus vaccine and prevention of gastroenteritis hospitalizations in Australia. Pediatrics 2010; 126:e506-12.
25. Muhsen K, Shulman L, Kasem E, et al. Effectiveness of rotavirus vaccines for prevention of rotavirus gastroenteritis-associated hospitalizations in Israel: a case-control study. Hum Vaccin 2010; 6:450-4.
26. Castilla J, Baristain X, Martinez-Artola V, et al. Effectiveness of rotavirus vaccines in preventing cases and hospitalizations due to rotavirus gastroenteritis in Navarre, Spain. Vaccine 2012; 30:539-43.